<?xml version="1.0" encoding="UTF-8"?><protocol_summary><protocol><id>15038</id><no>SANOFI-EFC17919</no><status>Open</status><title>Master protocol of two independent, randomized, double-blind, Phase 3 studies comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis</title><secondary_protocol_no>EFC17919</secondary_protocol_no><nct_id>NCT06141473</nct_id><sponsor_type>Industrial</sponsor_type><age_group>Adult</age_group><treatment_type>Treatment</treatment_type><disease_site>Other</disease_site><PI>Amjad, Faria</PI><institution>Georgetown University Medical Center; Lombardi Comprehensive Cancer Center</institution><management_group>GUMC Neurology</management_group></protocol><sipVersion>2026.1.0 Build 16</sipVersion><copyright> &lt;a href="https://advarra.com" target="_blank"&gt;&amp;copy; 2026 Advarra, Inc.&lt;/a&gt; </copyright></protocol_summary>